Company Insights

ADCT customer relationships

Explore interactive graphBrowse insights index
ADCT customer relationship map

ADC Therapeutics (ADCT): customer relationships that govern commercial upside and downside

ADC Therapeutics commercializes a single approved oncology product, ZYNLONTA, and monetizes primarily through product sales in the United States supported by a distributor network and supplemented by financing and royalty arrangements. Investors should evaluate ADCT on three axes: channel concentration (wholesale distributors), revenue concentration (one core product), and contractual financial flexibility (royalty and PIPE arrangements). Learn more about relationship intelligence for portfolio due diligence at https://nullexposure.com/.

How ADC makes money and what that implies for customers and partners

ADC Therapeutics operates as a clinical-stage oncology company that transitioned into commercialization with ZYNLONTA. Revenue recognition is product-sale driven, concentrated in North America, and routed largely through wholesale distributors, which creates both scale opportunities and counterparty concentration risk. The company’s contracts also embed significant gross-to-net mechanics—government rebates, chargebacks and distributor fees—that directly compress realized revenue and increase dependency on payer/access dynamics.

  • Contracting posture: ADCT sells through distributors and directly to U.S. providers, with formal agreements that create operational reliance on a few large wholesalers.
  • Concentration and criticality: The business is highly concentrated around ZYNLONTA; distributor partners account for a meaningful share of channel throughput.
  • Maturity: Commercial operations are active but early-stage relative to diversified pharma peers; cash and financing arrangements supplement operational cash flow.

For more granular relationship mapping and signals that feed investor workflows, visit https://nullexposure.com/.

Who ADCT sells to — relationship-by-relationship

AmerisourceBergen Corporation

AmerisourceBergen is listed by ADC Therapeutics in its FY2024 10‑K under customer concentration disclosures, indicating AmerisourceBergen functions as a material wholesale channel for product distribution. This positions AmerisourceBergen as a primary distribution conduit for ADCT’s U.S. sales (ADC Therapeutics FY2024 10‑K, filed Dec 2024).

Cardinal Health

Cardinal Health appears in the same FY2024 10‑K customer-concentration section, confirming Cardinal is another major wholesale distributor in ADCT’s U.S. go‑to‑market. Cardinal’s inclusion underscores the company’s dependence on the traditional pharmaceutical wholesale network (ADC Therapeutics FY2024 10‑K, filed Dec 2024).

McKesson

McKesson is also named in ADCT’s FY2024 customer-concentration disclosures, completing the three large U.S. wholesalers that route ZYNLONTA into provider and pharmacy channels. McKesson’s role further concentrates ADCT’s channel exposure among the top U.S. distributors (ADC Therapeutics FY2024 10‑K, filed Dec 2024).

TCGX

TCGX led a recent private investment in public equity (PIPE) that provided ADC Therapeutics with $60 million in financing; the transaction signals investor support for near-term liquidity and continuing operations (Yahoo Finance coverage, Mar 9, 2026). For commercial relationship analysis, this establishes TCGX as a financing counterparty rather than a product customer.

Redmile Group

Redmile Group participated in the same PIPE alongside TCGX and existing investors, reflecting institutional capital commitment to ADCT’s strategy and capital plan (Yahoo Finance coverage, Mar 9, 2026). Like TCGX, Redmile is an investor counterparty with interests tied to corporate value and execution rather than distribution volume.

HealthCare Royalty

ADC Therapeutics amended its royalty purchase agreement with HealthCare Royalty to reduce change-of-control payments from $750 million to $150 million through the end of 2027 (and $200 million thereafter), a contractual revision designed to increase strategic flexibility and lower transaction-triggered liabilities (Intellectia news report, Mar 2026). This is a financing/royalty relationship that directly alters ADCT’s future cash obligations under corporate-change events.

Mid‑report read: what the relationships collectively signal for investors

The named wholesale distributors—AmerisourceBergen, Cardinal Health, and McKesson—confirm ADCT’s reliance on the established U.S. channel ecosystem. The company itself states product revenue is driven by U.S. sales of ZYNLONTA and is sold primarily through wholesale distributors, creating a concentrated routing model that amplifies counterparty risk if any distributor’s terms change or service is disrupted (ADC Therapeutics FY2024 10‑K).

Simultaneously, the presence of TCGX and Redmile as PIPE participants and the HealthCare Royalty amendment illustrate two things: ADCT is actively managing liquidity through equity and royalty finance, and the firm is restructuring contingent liabilities to preserve optionality in strategic transactions. The royalty amendment, in particular, reduces a material change-of-control cash outlay and therefore raises corporate flexibility for transactions or future financings (Intellectia news, Mar 2026).

For readers who want integrated counterparty intelligence that ties these commercial and financing relationships to credit and revenue scenarios, see more at https://nullexposure.com/.

Risk profile distilled from customer and contract signals

  • Revenue concentration risk is high. ADCT’s current product portfolio hinges on ZYNLONTA as the core revenue driver; distributor relationships route nearly all product sales in the U.S., increasing systemic exposure to channel terms and reimbursement dynamics (company disclosures, FY2024).
  • Channel concentration creates contractual leverage risk. Three wholesalers dominate distribution; any adverse pricing, service, or rebate negotiation could materially affect realized revenue.
  • Gross-to-net and government exposure compress margins. Company disclosures identify government rebates, chargebacks and the discarded drug rebate as built-in reductions to net selling price—these are structural margin constraints that scale with volume.
  • Financing relationships alter strategic runway. The PIPE and royalty amendment improved near-term liquidity and reduced contingent payout risk, but introduce investor dilution and longer-term contractual obligations that investors must weigh against commercialization upside.

Bottom line and investor actions

  • Key takeaway: ADC Therapeutics operates a tightly concentrated commercial model—U.S.-centric sales of a single flagship product funneled through three major wholesale distributors—while relying on structured financings to manage runway.
  • What to watch next: monitor distributor contract terms and gross-to-net trends, pipeline progress that would diversify revenue, and any further restructuring of royalty/financing obligations.

If you evaluate counterparty exposure for biotech investments, start an in-depth review at https://nullexposure.com/. For tailored relationship mapping and alerts on material customer or contract events for ADCT, visit https://nullexposure.com/ and request a briefing.